|
|
|
 |
FDA Approval Activities for this Drug…
Zemplar (paricalcitol injection), Abbott NDA 20-819/S7, S11 2/24/03 3/10/03 Zemplar (paricalcitol injection), 5 mcg/mL Abbott NDA 20-819/S-003 2/2/00 2/4/00 2/4/00 Zemplar Indicated: For the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. Zemplar (paricalcitol) Injection Abbott NDA 20-819 Zemplar (paricalcitol) Injection, Abbott Laboratories | Zemplar (paricalcitol) Capsules, Abbott Laboratories, Approval | Zemplar (paricalcitol) Injection, Abbott Labs, Labeling Revision | Zemplar (paricalcitol) Capsules, Abbott Laboratories, New or Modified Indication | Zemplar (paricalcitol) Capsules, Abbott Laboratories, New or Modified Indication | Zemplar (paricalcitol) Capsules, Abbott Laboratories, New or Modified Indication | Zemplar (paricalcitol) Capsules, Abbott Laboratories, Labeling Revision | Paricalcitol Capsules, TEVA Pharmaceuticals, Tentative Approval | Zemplar (paricalcitol) Injection, Abbott Laboratories, Labeling Revision | Zemplar (paricalcitol) Capsules, Abbott Laboratories, Labeling Revision | Zemplar (paricalcitol) Injection, Abbott Laboratories, Labeling Revision | Paricalcitol Injection, Sandoz Canada, Inc., Tentative Approval | Paricalcitol Injection, Sandoz, Inc., Approval | Paricalcitol Capsules, Dr. Reddy's Laboratories Ltd., Tentative Approval
  
|